Latest News

  • RESEARCH

    30 Jan 2026

    New Metabolic Data Reignite Interest in Liver-Targeted Lipid Drugs

  • PARTNERSHIPS

    20 Jan 2026

    Roche’s 89bio Deal Heats Up the Race for MASH Drugs

  • INSIGHTS

    19 Jan 2026

    A $160M Biotech Bet Points to Obesity Drugs’ Next Test

  • RESEARCH

    16 Jan 2026

    FDA Fast Tracks Dual-Action MASH Drug: Is Momentum Back?

Big Pharma’s Next Obesity Bet Comes in Pill Form

Lilly and Nimbus Therapeutics logos displayed to mark an obesity drug development partnership

PARTNERSHIPS

13 Jan 2026

Drugmakers push oral obesity pills into late trials, aiming to move weight loss care beyond injections and into mass-market medicine

Oral weight loss pills with measuring tape illustrating shift in obesity treatment

MARKET TRENDS

8 Jan 2026

Oral Weight Loss Pills Are Shaking Up Metabolic Care

Oral obesity drugs are widening access, shifting pricing power, and forcing drugmakers and health platforms to rethink how metabolic care ...

Pfizer research facility following Metsera acquisition in obesity drug strategy

PARTNERSHIPS

6 Jan 2026

Pfizer’s Metsera Deal Ignites a New Obesity Drug Arms Race

Pfizer’s Metsera buy sharpens its obesity strategy and signals a fiercer, faster fight for metabolic drug leadership

Ionis Pharmaceuticals sign representing liver-targeted drug research for MASH

RESEARCH

19 Dec 2025

Liver-First Drugs Redefine the Next Phase of the MASH Race

New 2025 data for Ionis ION224 highlight how liver-targeted drugs and GLP-1s may converge to reshape MASH care and deal-making

Business discussion reflecting FDA pilot voucher accelerating metabolic drug reviews

REGULATORY

18 Dec 2025

FDA Pilot Voucher Signals Faster Reviews for Metabolic Drugs

A new FDA pilot voucher could shrink review timelines for select obesity and diabetes drugs, stirring optimism and debate across the secto...

Colorful 3D rendering of mitochondria used in metabolic research

INNOVATION

17 Dec 2025

The Next Obesity Bet Lies Deep Inside Cells

As GLP-1 drugs dominate obesity care, a handful of biotechs are probing mitochondria, searching for new metabolic levers inside the cell

Zealand Pharma and OTR Therapeutics logos displayed for metabolic drug partnership

PARTNERSHIPS

16 Dec 2025

Zealand Pharma Expands Metabolic Ambitions With OTR Deal

Zealand Pharma and OTR Therapeutics strike a collaboration to develop oral metabolic drugs, widening the field beyond injectables

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.